A 10-year-old whistleblower lawsuit filed by a former Abbott (NYSE:ABT) sales rep, over the alleged off-label marketing of biliary stents, finally went to trial in Dallas yesterday. Plaintiff Kevin Colquitt, a former rep for Abbott’s Guidant division, sued Abbott, Johnson & Johnson (NYSE:JNJ) and Boston Scientific (NYSE:BSX) in 2006, claiming that they marketed the use of biliary stents to treat peripheral artery disease. (The magistrate overseeing […]
Xlumena won FDA approval to market its Axios stent and delivery system, landing approval through the FDA’s less-stringent de novo review pathway.
The stent is the 1st specifically designed for the drainage of a pancreatic pseudocyst by creating a new, temporary opening between the pancreas and the gastrointestinal tract.
Boston Scientific Corp. (NYSE:BSX) sued Cook Group, a slew of its subsidiaries and a group of Korean firms, alleging infringement of four endoscopic stent patents covering devices to treat the digestive system.
The lawsuit, filed in the U.S. District Court for Massachusetts, accuses Warsaw, Indiana-based Cook and the subsidiaries (including Cook Ireland Ltd.) of violating the quartet of patents with its Evolution stenting system, according to court documents.
Viking Systems Inc. (OTC:VKNG) extended its supply contract with Boston Scientific Corp. (NYSE:BSX).
The Westborough, Mass.-based company provides the camera, light source and accessories designed specifically for Boston Scientific’s SpyGlass direct visualization system.
Boston Scientific Corp. (NYSE:BSX) enrolled the first patient in a clinical trial of its WallFlex biliary stent for the treatment of benign bile duct strictures.
The Natick, Mass.-based medical device colossus said it plans to enroll 187 patients at 11 centers worldwide over the next 18 months for the trial, which will evaluate the removal of the stents from patients with benign bile duct strictures and the effectiveness of temporary stenting for long-term, benign biliary stricture resolution.